Nutra Pharma Announces Plans for Registration in South Africa
Nutra Pharma is announcing the beginning of the process for the registration of their homeopathic pain drug, Nyloxin(tm), in South Africa
Coral Springs, FL US, August 22, 2013 /FSC/ - Nutra Pharma Corporation (OTCQB: NPHC), a biotechnology company that is developing treatments for Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain, announced today that they have begun the process of registering their homeopathic treatment for chronic pain, Nyloxin(tm),in the country of South Africa.
"According to ImpactRX, the South African market for analgesics is over $200M," commented Rik J Deitsch, CEO of Nutra Pharma Corporation. "We have already engaged a firm in South Africa to begin the registration process and we believe that Nyloxin will be well-accepted in this marketplace. Our goal is to be able to market the product in South Africa by mid-2014," he continued. "This may also allow for the future registration of our other products as well as continuing research for our HIV drug, RPI-MN," he concluded.
The Company recently reported their issuance of Trademarks for Cobroxin(r) in Colombia and India, as well as patents for the use of cobra venom in the treatment of pain that have been issued in the United States and India.
Nyloxin(tm) is an over-the-counter (OTC) pain reliever clinically proven to treat moderate to severe (Stage 2) chronic pain. Nyloxin(tm) is currently available in the United States as an oral spray for treating back pain, neck aches, headaches, joint pain, migraines, and neuralgia, and as a topical gel for treating joint pain, neck pain, arthritis pain, and pain from repetitive stress. In addition to its everyday strength formulation, Nyloxin(tm) is also offered in an extra strength formula for more advanced, Stage 3, chronic pain.
About Nutra Pharma Corp.
Nutra Pharma Corporation operates as a biotechnology company specializing in the acquisition, licensing, and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune, and infectious diseases, including Multiple Sclerosis (MS), Human Immunodeficiency Virus (HIV), Adrenomyeloneuropathy (AMN) and Pain. The Company markets several drug products for sale for the treatment of pain under the brands Cobroxin(r) and Nyloxin(tm). For additional information about Nutra Pharma or Nyloxin(tm), visit: http://www.NutraPharma.com or http://www.nyloxin.net.
SEC Disclaimer
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The South African registration of Nyloxin(tm) should not be construed as an indication in any way whatsoever of the future value of the Company's common stock or its present or future financial condition. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov.
Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
# # #
Contact:Nutra Pharma Corp.
Nina Goldstein
877-895-5647
IR@nutrapharma.com
Maximum News Dissemination by FSCwire. http://www.fscwire.com